AU6345794A - Ipsapirone medicament formulation - Google Patents

Ipsapirone medicament formulation

Info

Publication number
AU6345794A
AU6345794A AU63457/94A AU6345794A AU6345794A AU 6345794 A AU6345794 A AU 6345794A AU 63457/94 A AU63457/94 A AU 63457/94A AU 6345794 A AU6345794 A AU 6345794A AU 6345794 A AU6345794 A AU 6345794A
Authority
AU
Australia
Prior art keywords
ipsapirone
medicament formulation
medicament
formulation
ipsapirone medicament
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU63457/94A
Inventor
Not Given Name
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer AG
Original Assignee
Bayer AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer AG filed Critical Bayer AG
Publication of AU6345794A publication Critical patent/AU6345794A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU63457/94A 1993-06-15 1994-05-31 Ipsapirone medicament formulation Abandoned AU6345794A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE4319760A DE4319760A1 (en) 1993-06-15 1993-06-15 Ipsapiron drug preparation
DE4319760 1993-06-15

Publications (1)

Publication Number Publication Date
AU6345794A true AU6345794A (en) 1994-12-22

Family

ID=6490360

Family Applications (1)

Application Number Title Priority Date Filing Date
AU63457/94A Abandoned AU6345794A (en) 1993-06-15 1994-05-31 Ipsapirone medicament formulation

Country Status (16)

Country Link
EP (1) EP0629402A1 (en)
JP (1) JPH06345649A (en)
KR (1) KR950000150A (en)
CN (1) CN1099263A (en)
AU (1) AU6345794A (en)
CA (1) CA2125620A1 (en)
CZ (1) CZ146494A3 (en)
DE (1) DE4319760A1 (en)
FI (1) FI942803A (en)
HU (1) HUT70759A (en)
IL (1) IL109993A0 (en)
NO (1) NO942228L (en)
NZ (1) NZ260732A (en)
PL (1) PL303822A1 (en)
SK (1) SK72494A3 (en)
ZA (1) ZA944187B (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9706089D0 (en) * 1997-03-24 1997-05-14 Scherer Ltd R P Pharmaceutical composition
OA11740A (en) * 1998-12-24 2005-05-13 Janssen Pharmaceutica Nv Controlled release galantamine composition.
WO2004103338A1 (en) * 2003-05-19 2004-12-02 Bioprogress Plc Adhesives and film modifying compositions
PL4062913T3 (en) * 2020-09-02 2024-07-22 Beijing Biostar Pharmaceuticals Co., Ltd. Solid oral formulation of utidelone

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0386440T3 (en) * 1989-02-11 1992-09-14 Bayer Ag Medicines with controlled release of active substance
DD297767A5 (en) * 1990-03-06 1992-01-23 Bayer Aktiengesellschaft,De MEDICINAL PRODUCTS WITH CONTROLLED ACTIVE INGREDIENTS
JPH04360826A (en) * 1991-06-07 1992-12-14 Bayer Yakuhin Kk Controlled release pharmaceutical preparation

Also Published As

Publication number Publication date
NZ260732A (en) 1996-02-27
JPH06345649A (en) 1994-12-20
FI942803A0 (en) 1994-06-13
FI942803A (en) 1994-12-16
EP0629402A1 (en) 1994-12-21
CN1099263A (en) 1995-03-01
PL303822A1 (en) 1995-01-09
CZ146494A3 (en) 1995-01-18
KR950000150A (en) 1995-01-03
SK72494A3 (en) 1995-04-12
ZA944187B (en) 1995-02-08
CA2125620A1 (en) 1994-12-16
NO942228L (en) 1994-12-16
NO942228D0 (en) 1994-06-14
HUT70759A (en) 1995-10-30
IL109993A0 (en) 1994-10-07
DE4319760A1 (en) 1994-12-22
HU9401771D0 (en) 1994-09-28

Similar Documents

Publication Publication Date Title
AU2087992A (en) Pharmaceutical combination formulation
AU1176995A (en) Taxol formulation
AU696232B2 (en) Syringe
AU6995396A (en) Pharmaceutical formulation
AU7305594A (en) Physiologically active substance-prolonged releasing-type pharmaceutical preparation
AU3888793A (en) Novel medicament
AU3062392A (en) Pdgf gel formulation
AU7085594A (en) Syringe
AU7961094A (en) Picosulphate dosage form
AU6973396A (en) Pharmaceutical formulation
AU1522992A (en) Optimized tablet formulation
AU2954692A (en) Medical preparations
AU6388494A (en) Skin care composition
AU6204894A (en) Medicament presentation
AU7582696A (en) Pharmaceutical formulation
AU1189392A (en) Pharmaceutical agent
AU2392492A (en) Pharmaceutical composition
AU6629494A (en) Membrane-permeant second messengers
AU6204994A (en) Medicament presentation
AU7235394A (en) Stabilized formulation
AU6345794A (en) Ipsapirone medicament formulation
AU7244094A (en) Lavendamycin analogs, their use and preparation
AU7318994A (en) Thf-gamma2 analogs and pharmaceutical compositions comprising them
AU1740692A (en) New medicinal use
AU5049098A (en) Pharmaceutical formulation